Ramucirumab
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
HTNGLOMTMA
ModerateOpen →
VEGFR TKI
Fruquintinib
Fruzaqla · Fruq
A highly selective VEGFR1-3 TKI for refractory colorectal cancer — hypertension and proteinuria, by class.
ModerateVEGFR tyrosine-kinase inhibitor · approved 2023
Refractory metastatic colorectal cancer
Signature kidney injury
Hypertension
Hypertension and proteinuria are characteristic VEGFR-TKI class effects; in the FRESCO-2 safety analysis hypertension was among the most frequent grade ≥3 adverse events, with proteinuria also reported. Renal-specific TMA is rare but described across the VEGF-inhibitor class.
Source: Eng et al., Oncologist 2025 (FRESCO-2 safety)
Mechanism of kidney injury
VEGF-A signaling through VEGFR-2 maintains glomerular endothelial fenestrae and the podocyte–endothelial crosstalk of the filtration barrier and supports endothelial nitric-oxide production. Pharmacologic VEGF blockade reduces NO-mediated vasodilation (raising systemic blood pressure) and damages the glomerular endothelium and podocyte, opening the filtration barrier to cause proteinuria; histologically this manifests as a renal-limited thrombotic microangiopathy and, with downstream kinase effects, podocytopathies (minimal change/FSGS-like lesions). Sustained or high-grade blockade can precipitate overt glomerular TMA with hemolysis.
Clinical presentation
New or worsened hypertension and proteinuria (often sub-nephrotic, occasionally nephrotic) with usually preserved or mildly reduced GFR. Rarely TMA: microangiopathic hemolytic anemia, schistocytes, thrombocytopenia and worsening renal function.
Onset
Within weeks of starting therapy (hypertension often earliest).
Reversibility
Reversible
Anticancer mechanism
Potent, highly selective oral inhibitor of VEGFR-1, -2 and -3 tyrosine kinases, blocking VEGF-driven tumor angiogenesis with relatively little off-target kinase activity. Approved for previously treated metastatic colorectal cancer.
Management
Control blood pressure to target (ACE inhibitors/ARBs are rational given concurrent proteinuria); monitor and manage proteinuria with dose interruption/reduction for nephrotic-range or rising protein; discontinue for confirmed TMA and manage supportively. Most hypertension/proteinuria reverses on dose modification or cessation.
Risk factors
- Pre-existing hypertension
- Baseline proteinuria or CKD
- Prior anti-angiogenic therapy (bevacizumab, other VEGFR-TKIs)
Prevention
- Baseline and on-treatment blood-pressure and urine-protein (UPCR/dipstick) monitoring
- Early, proactive antihypertensive therapy
- Dose modification per proteinuria/hypertension grade
Note · Toxicity mirrors the established VEGF/VEGFR class signature and is managed with standard anti-angiogenic monitoring. The JASN VEGF-nephrotoxicity framework explains why direct-antibody VEGF blockade favors TMA while VEGFR-TKIs add podocytopathy.
Clinical depth
Renal dose adjustment
No specific renal dose adjustment for mild–moderate impairment; not adequately studied in severe renal impairment/ESKD. Modify dose for grade of hypertension/proteinuria per label rather than for GFR alone.
Dialyzability & ESKD dosing
Highly protein-bound small molecule with hepatic metabolism; not expected to be appreciably dialyzed. No established ESKD dosing — monitor blood pressure and proteinuria closely.
Differential diagnosis
VEGF-TKI hypertension/proteinuria/TMA vs pre-existing diabetic or hypertensive nephropathy vs other-cause nephrotic syndrome; schistocytes + thrombocytopenia + LDH point to drug-induced TMA rather than simple proteinuria.
Monitoring
- Blood pressure (including home monitoring) weekly early, then each cycle
- Urine protein (dipstick/UPCR) at baseline and periodically
- CBC and creatinine; add LDH/haptoglobin/smear if TMA suspected
Key trials & series
- FRESCO (China) and FRESCO-2 (global) phase III colorectal trials
- Eng Oncologist 2025 FRESCO-2 dedicated safety analysis
Clinical pearls
- Hypertension and proteinuria are predictable VEGFR-TKI class effects — monitor BP and urine protein from the first cycle.
- Prefer an ACE inhibitor or ARB for the hypertension since it also addresses the concurrent proteinuria.
- Schistocytes with falling platelets and rising LDH signal drug-induced TMA — stop the drug.
- Antibody VEGF blockade classically causes TMA; VEGFR-TKIs add podocytopathy (MCD/FSGS-like) — the lesion depends on the agent.
Where it strikes
Nephron segments
Glomerulus
Filtration barrier (podocytes + endothelium)
Injury signatures
HypertensionGlomerular Injury / Proteinuria
Beyond the kidney
Class-level context for the major non-renal toxicities of vegfr tkis.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Hypertension, arterial/venous thrombosis, bleeding, impaired wound healing
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- LV dysfunction; QT (some TKIs)
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Diarrhea, perforation/fistula
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Hand-foot skin reaction
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
PMIDFruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.Eng C et al. · Oncologist 2025 · PMID 40163688Dedicated FRESCO-2 safety analysis: hypertension and proteinuria as key class adverse events.LandmarkTherapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.Estrada CC et al. · J Am Soc Nephrol 2019 · PMID 30642877Definitive mechanistic review: VEGF/VEGFR blockade causes TMA, hypertension, proteinuria and podocytopathy via endothelial/podocyte injury.PMIDCurrent Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features.Tonooka A et al. · J Nippon Med Sch 2021 · PMID 34840210Histopathology of anti-VEGF/VEGFR renal lesions (TMA-like glomerular injury, podocytopathy).PMIDNephrotoxicity of anti-angiogenesis drugs.Grechukhina KS et al. · Ter Arkh 2020 · PMID 33346501Review of antiangiogenic nephrotoxicity — hypertension, proteinuria, nephrotic syndrome and TMA.PMIDPathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.Zhang PL et al. · Ann Clin Lab Sci 2021 · PMID 34921042Biopsy correlation of VEGF-antagonist renal injury (TMA and ATN), illustrating the glomerular mechanism.PMIDRenal Side Effects of Novel Molecular Targeted Oncologic Agents.Fenoglio R et al. · G Ital Nefrol 2023 · PMID 38007829Biopsy series confirming TMA as the dominant lesion of anti-angiogenic agents — supporting the fruquintinib glomerular signal.
Related agents
Other agents sharing the same signature kidney injury.